Grifols Future Growth

Future criteria checks 4/6

Grifols is forecast to grow earnings and revenue by 36.6% and 6.7% per annum respectively. EPS is expected to grow by 36.3% per annum. Return on equity is forecast to be 12.2% in 3 years.

Key information

36.6%

Earnings growth rate

36.3%

EPS growth rate

Biotechs earnings growth	40.8%
Revenue growth rate	6.7%
Future return on equity	12.2%
Analyst coverage	Good
Last updated	18 Dec 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:G0F - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	8,211	775	861	1,167	12
12/31/2025	7,680	596	601	918	13
12/31/2024	7,134	232	627	579	13
9/30/2024	7,006	161	209	527	N/A
6/30/2024	6,811	166	77	377	N/A
3/31/2024	6,656	189	-187	105	N/A
12/31/2023	6,592	59	-87	208	N/A
9/30/2023	6,535	23	-217	119	N/A
6/30/2023	6,479	-5	-496	-123	N/A
3/31/2023	6,358	47	-485	-107	N/A
12/31/2022	6,064	208	-386	-11	N/A
9/30/2022	5,549	149	-272	50	N/A
6/30/2022	5,207	66	-36	289	N/A
3/31/2022	5,016	112	137	454	N/A
12/31/2021	4,933	189	282	597	N/A
9/30/2021	5,044	361	400	727	N/A
6/30/2021	5,199	667	597	909	N/A
3/31/2021	5,231	562	847	1,183	N/A
12/31/2020	5,340	619	748	1,110	N/A
9/30/2020	5,392	687	663	1,081	N/A
6/30/2020	5,353	557	551	964	N/A
3/31/2020	5,235	697	425	842	N/A
12/31/2019	5,099	625	157	569	N/A
9/30/2019	4,961	552	309	668	N/A
6/30/2019	4,790	565	275	634	N/A
3/31/2019	4,620	568	147	477	N/A
12/31/2018	4,487	597	430	737	N/A
9/30/2018	4,332	699	365	680	N/A
6/30/2018	4,246	704	N/A	712	N/A
3/31/2018	4,279	672	N/A	789	N/A
12/31/2017	4,318	663	N/A	842	N/A
9/30/2017	4,348	571	N/A	751	N/A
6/30/2017	4,291	559	N/A	765	N/A
3/31/2017	4,153	554	N/A	640	N/A
12/31/2016	4,050	545	N/A	553	N/A
9/30/2016	4,014	537	N/A	683	N/A
6/30/2016	3,986	535	N/A	652	N/A
3/31/2016	3,985	529	N/A	767	N/A
12/31/2015	3,935	532	N/A	743	N/A
9/30/2015	3,789	533	N/A	755	N/A
6/30/2015	3,645	507	N/A	836	N/A
3/31/2015	3,466	478	N/A	888	N/A
12/31/2014	3,355	470	N/A	979	N/A
9/30/2014	3,133	417	N/A	882	N/A
6/30/2014	2,972	388	N/A	712	N/A
3/31/2014	2,856	376	N/A	625	N/A
12/31/2013	2,742	346	N/A	592	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: G0F's forecast earnings growth (36.6% per year) is above the savings rate (1%).

Earnings vs Market: G0F's earnings (36.6% per year) are forecast to grow faster than the German market (20.6% per year).

High Growth Earnings: G0F's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: G0F's revenue (6.7% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: G0F's revenue (6.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: G0F's Return on Equity is forecast to be low in 3 years time (12.2%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/19 00:46
End of Day Share Price	2024/12/19 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Grifols, S.A. is covered by 42 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Elena Fernández	Ahorro Corporación
Kamla Singh	AlphaValue
Guilherme Sampaio	Banco BPI, S.A.

Grifols Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Recent updates

Flat Footed Calls for Prompt Governance Overhaul at Grifols

Brookfield Capital Partners (Uk) Limited and Grifols family cancelled the acquisition of remaining stake in Grifols, S.A. (BME:GRF).

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Grifols Announces Management Changes

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.